BROLUCIZUMAB (BEOVU): A Comprehensive Guide for Patients

Table of Contents

• What is Brolucizumab?
• How Brolucizumab Works
• Medical Conditions Treated with Brolucizumab
• Administration and Dosing
• Efficacy and Benefits
• Treatment Regimens
• Side Effects and Safety
• Comparison with Other Treatments
• Patient Considerations

What is Brolucizumab?

Brolucizumab (brand name BEOVU®) is a medication used to treat eye diseases, primarily neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It belongs to a class of medications known as anti-VEGF (anti-vascular endothelial growth factor) agents ^[1]. This medication is relatively new to the market compared to other anti-VEGF treatments.

Brolucizumab is a humanized single-chain antibody fragment (scFv) that inhibits vascular endothelial growth factor A (VEGF-A). It is also known by research codes RTH258 and ESBA1008 during its development phase ^[2]. The medication is delivered as an intravitreal injection, meaning it is injected directly into the eye.

How Brolucizumab Works

Brolucizumab works by targeting and inhibiting VEGF-A, a protein that promotes the growth of abnormal blood vessels in the eye. In conditions like wet AMD and DME, these abnormal blood vessels can leak fluid and blood into the retina, causing vision problems ^[3].

The key characteristics of brolucizumab that distinguish it from other anti-VEGF agents include:

• Smaller molecule size: As a single-chain antibody fragment, brolucizumab is much smaller than other anti-VEGF medications, which may allow for better tissue penetration and higher dosing concentration ^[4].
• Higher molar concentration: Due to its smaller size, more molecules of brolucizumab can be delivered in a single injection compared to other anti-VEGF drugs, potentially providing longer-lasting effects ^[5].
• Tissue penetration: The smaller size may enable better penetration through the layers of the retina to reach the targeted tissues ^[3].

Medical Conditions Treated with Brolucizumab

Brolucizumab is primarily used to treat:

Neovascular (Wet) Age-Related Macular Degeneration

Wet AMD is characterized by the growth of abnormal blood vessels under the macula (the central part of the retina responsible for detailed central vision). These vessels can leak fluid and blood, causing distortion and loss of central vision ^[1].

Diabetic Macular Edema

DME occurs when blood vessels in the retina leak fluid into the macula due to complications from diabetes. This causes the macula to swell, which can blur and distort central vision ^[6].

Macular Polypoidal Choroidal Vasculopathy (PCV)

Some clinical trials have also examined brolucizumab's effectiveness in treating PCV, a subtype of AMD characterized by abnormal vessel networks with polyp-like dilations ^[7].

Dystrophy-Related Macular Neovascularization

Research has been conducted on using brolucizumab for dystrophy-related macular neovascular degeneration, which is a vision-threatening condition ^[8].

Administration and Dosing

Brolucizumab is administered through intravitreal injection, meaning it is injected directly into the eye's vitreous humor (the gel-like substance that fills the eyeball). This procedure is typically performed in an ophthalmologist's office after the eye has been numbed with local anesthetic drops ^[1].

The standard dosing options include:

• For nAMD: 6 mg (0.05 mL of solution) per eye ^[1]
• For DME: Studies have evaluated both 3 mg and 6 mg doses, with 6 mg being the most common ^[6]

The medication is available as a pre-filled syringe for single use only, containing 6 mg of brolucizumab in 0.05 mL of solution (120 mg/mL) ^[5].

Efficacy and Benefits

Multiple clinical trials have demonstrated the efficacy of brolucizumab in treating both nAMD and DME. Key benefits include:

Visual Acuity Improvement

Patients treated with brolucizumab have shown improvements in best-corrected visual acuity (BCVA), which is the clearest vision possible with correction such as glasses ^[9]. For example, a significant number of patients gained 15 or more letters on standardized eye charts after treatment ^[10].

Anatomical Improvements

Brolucizumab has demonstrated strong ability to reduce retinal fluid, including:

• Reduction in central subfield thickness (CSFT): Measurement of the thickness of the central retina, with reductions indicating decreased swelling ^[11]
• Resolution of intraretinal fluid (IRF) and subretinal fluid (SRF): Many patients achieve complete fluid resolution, which is important for long-term visual outcomes ^[9]

Duration of Effect

One of brolucizumab's key advantages is its potential for longer intervals between treatments for many patients ^[12]. This is particularly beneficial for reducing treatment burden.

Disease Activity Control

Studies have shown that brolucizumab can effectively control disease activity, with a significant proportion of patients maintaining stable disease on extended treatment intervals ^[13].

Treatment Regimens

Brolucizumab is typically administered following specific regimens designed to maximize effectiveness while minimizing the number of injections:

Loading Phase

Treatment usually begins with a loading phase consisting of:

• For nAMD: Three monthly injections (at weeks 0, 4, and 8) ^[1]
• For DME: Five loading doses at 6-week intervals have been studied ^[14]

Maintenance Phase

After the loading phase, several maintenance regimens are possible:

Fixed Interval

Some patients follow a fixed schedule, typically:

• Every 8 weeks (q8w) or
• Every 12 weeks (q12w) ^[1]

Treat-and-Extend (T&E)

This personalized approach involves:

• Starting with fixed intervals after the loading phase
• Gradually extending the time between injections (by 2-4 weeks) if the disease remains stable
• Reducing intervals if signs of disease activity appear ^[15]

Personalized Treatment Interval

Some studies have examined personalized treatment approaches where:

• Treatment intervals are determined based on individual patient response
• Some patients may achieve treatment intervals of up to 16-20 weeks ^[7]
• Disease activity assessments (DAAs) are conducted to determine whether treatment intervals should be extended, maintained, or shortened ^[16]

Side Effects and Safety

As with any medication, brolucizumab can cause side effects. It's important for patients to be aware of these potential effects and to report any concerning symptoms to their healthcare provider promptly.

Common Side Effects

The most common side effects associated with brolucizumab include:

• Eye redness (conjunctival hyperemia)
• Eye pain
• Floaters (small dark spots or squiggly lines in vision)
• Increased intraocular pressure (temporary after injection)
• Eye discomfort or irritation ^[17]

Serious Side Effects

More serious, but less common, side effects that require immediate medical attention include:

• Intraocular inflammation (IOI): Inflammation inside the eye that may present as eye pain, increased sensitivity to light, or changes in vision ^[1]
• Retinal vasculitis: Inflammation of the blood vessels in the retina ^[18]
• Retinal vascular occlusion: Blockage of blood vessels in the retina that can lead to vision loss ^[18]
• Endophthalmitis: Serious infection inside the eye, which is rare but can occur with any intravitreal injection ^[19]

Monitoring and Management

To ensure safety during treatment:

• Regular follow-up appointments are essential to monitor for any signs of side effects
• Patients should report any new eye symptoms promptly
• Physicians may conduct specific tests to evaluate eye health during and after treatment ^[20]

Safety Profile

Safety data from clinical trials and real-world studies provide information on the incidence of adverse events. While most patients tolerate brolucizumab well, awareness of potential side effects is important for both patients and healthcare providers ^[17].

Comparison with Other Treatments

Brolucizumab is one of several anti-VEGF medications used to treat nAMD and DME. Understanding how it compares to other treatments can help patients and doctors make informed decisions.

Compared to Aflibercept (Eylea)

Aflibercept is another commonly used anti-VEGF medication. Studies comparing brolucizumab to aflibercept have shown:

• Similar improvements in visual acuity
• Potentially superior fluid resolution with brolucizumab
• Longer treatment intervals possible with brolucizumab for some patients
• Different safety profiles that should be considered when selecting treatment ^[21]

Compared to Ranibizumab (Lucentis)

Ranibizumab was one of the first anti-VEGF medications approved for eye conditions. Compared to ranibizumab, brolucizumab:

• May allow for less frequent injections in some patients
• Has shown comparable visual acuity outcomes
• Has a different molecular structure (smaller size) that may affect tissue penetration ^[5]

Treatment Selection Considerations

Factors that may influence the choice between brolucizumab and other anti-VEGF treatments include:

• Individual patient response to previous treatments
• Presence of persistent fluid despite treatment with other agents
• Patient preference regarding treatment frequency
• Specific patient risk factors for potential side effects ^[22]

Patient Considerations

When considering brolucizumab treatment, patients should be aware of several important factors:

Treatment Expectations

• Treatment Duration: Anti-VEGF therapy, including brolucizumab, is typically a long-term treatment. Most patients with nAMD or DME will need ongoing injections to maintain vision gains and prevent disease progression ^[23].
• Follow-up Requirements: Regular follow-up appointments are essential for monitoring treatment response and adjusting treatment intervals as needed.
• Gradual Improvement: Vision improvement may be gradual, and maximum benefits may take several months to achieve ^[24].

Quality of Life Impact

Studies using the Visual Function Questionnaire-25 (VFQ-25) have shown improvements in vision-related quality of life with brolucizumab treatment, including benefits in:

• Near and distance activities
• Social functioning
• Mental health
• Dependency
• Driving ^[25]

Cost and Access

• Insurance Coverage: Coverage for brolucizumab varies by insurance plan and country. Patients should check with their insurance provider regarding coverage details.
• Patient Assistance Programs: Some pharmaceutical companies offer assistance programs for eligible patients who have difficulty affording their medications.
• Healthcare System Variation: Availability and coverage of brolucizumab may vary significantly between countries and healthcare systems ^[26].

Shared Decision Making

The decision to use brolucizumab should involve:

• Discussion of Benefits and Risks: Patients should understand both potential benefits and possible side effects.
• Consideration of Alternatives: Discussion of other available treatment options.
• Patient Preferences: Consideration of patient preferences regarding treatment frequency and goals ^[27].

Brolucizumab represents an important treatment option for patients with nAMD and DME. By understanding the medication's mechanism, benefits, risks, and treatment process, patients can participate more actively in decisions about their eye care and treatment plan.